Get Premium Access
Info

Scriptnotes Podcast

Screenwriters John August and Craig Mazin discuss screenwriting and related topics in the film and television industry, everything from getting stuff written to the vagaries of copyright and work-for-hire law.
RSS Feed Subscribe in iTunes Premium Podcasts
2017
June
May
April
March
February
January


2016
December
November
October
September
August
July
June
May
April
March
February
January


2015
December
November
October
September
August
July
June
May
April
March
February
January


2014
December
November
October
September
August
July
June
May
April
March
February
January


2013
December
November
October
September
August
July
June
May
April
March
February
January


2012
December
November
October
September
August
July
June
May
April
March
February
January


2011
December
November
October
September
August


All Episodes
Archives
Premium Episodes
Now displaying: Page 1
Get access to all episodes from SCRIPTNOTES for just 1.99 a month with Premium Access through MyLibsyn.
Jul 24, 2012

Craig and John tackle a question screenwriters ask themselves at every stage in their careers: of all things I could write, which thing should I write?

For working screenwriters, these questions are complicated by rights and money and personalities. But for the aspiring screenwriter, the choice is just as daunting. A screenplay is a huge undertaking, involving months or years of work. Each script carries an opportunity cost: choosing to write this project means not writing something else, or at the very least pushing it further back.

While the variables are different in every case, John and Craig offer some framework for answering the question.

Also this week, John discusses the death of Richard Zanuck, who produced three of his movies. From listener questions, we look at pitch-fests, illegal acts, and shows about your buddies.

And in cool things, Craig talks e-cigarettes while John has mixed opinions on the Nexus 7.

LINKS:

UPDATE 7-26-12: The transcript of this episode can be found here.

0 Comments